Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sacituzumab govitecan + cisplatin + avelumab
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
This drug is an **experimental combination therapy** consisting of three agents: - **sacituzumab govitecan**, an antibody-drug conjugate targeting Trop-2 and delivering the cytotoxic payload SN-38, - **cisplatin**, a platinum-based chemotherapeutic agent that crosslinks DNA to induce apoptosis, - **avelumab**, a monoclonal antibody checkpoint inhibitor targeting PD-L1 to promote anti-tumor immune responses. This multi-agent combination is being investigated for advanced solid tumors, leveraging complementary mechanisms: targeted cytotoxicity, DNA damage, and immune checkpoint blockade.
02
Targets
DNATOP1 (DNA Topoisomerase I)TACSTD2 (Tumor-associated calcium signal transducer 2)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on sacituzumab govitecan + cisplatin + avelumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sacituzumab govitecan + cisplatin + avelumab.